Lee’s Phar­ma to de­vel­op Windtree drug in Chi­na; Acurx shares PhI­Ib an­tibi­ot­ic da­ta; Grana­ta rais­es $14M

Plus, news about Pro­ta Ther­a­peu­tics and Vaxart:

Windtree Ther­a­peu­tics inks deal with Hong Kong group: Per the terms, Lee’s Phar­ma­ceu­ti­cal will pay Windtree up to $138.1 mil­lion to de­vel­op and com­mer­cial­ize its acute heart fail­ure and car­dio­genic shock treat­ment in Greater Chi­na. The drug is­tarox­ime ac­ti­vates SER­CA2a. Windtree’s stock $WINT was down about 13% on Wednes­day morn­ing. — Jaimy Lee 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER